A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing, advanced solid tumors.

3552Background: Delta-like 3 (DLL3) is highly and specifically expressed in solid tumors, such as neuroendocrine carcinomas (NECs), malignant melanoma (MM), and medullary thyroid carcinoma (MTC). R...